Read the full comparison
What to verify
- Look up the dispensing pharmacy’s legal name and active license in your state board of pharmacy database.
- Ask the seller to identify the active ingredient and confirm that semaglutide sodium or acetate will not be dispensed.
- Verify the prescriber’s name, professional license and availability for questions after delivery.
- Request the exact container, concentration and measurement units before paying.
- Compare the offer’s full recurring cost with current insurance benefits and official manufacturer-direct pricing.
- Confirm in writing what happens if the pharmacy, formulation, price or shipment condition changes.
Review overview
The key difference is not only price. It is whether the product has gone through FDA approval, what pharmacy prepares it, and what clinical support exists after payment.
Last checked Jul 5, 2026
Safety comparison note
Keep this comparison conservative. It should explain the difference between FDA-approved medications and compounded products without giving personalized medical or dosing advice.
- Use FDA sources for approval language
- Avoid implying compounded products are identical to brands
- Push medical decisions back to clinicians
What FDA approval changes
FDA-approved medicines such as Wegovy and Zepbound have approved prescribing information, manufacturing controls and label language that clinicians can reference. A compounded GLP-1 product is made by a compounding pharmacy for a specific context and is not FDA-approved as a finished product. That distinction matters even when the active ingredient name sounds familiar.
- Ask whether the exact product is FDA-approved or compounded.
- Do not use the word generic unless an approved generic actually exists.
- Request the pharmacy name and formulation before paying.
FDA warnings and 2026 enforcement context
FDA has warned about unapproved GLP-1 drugs used for weight loss, fraudulent compounded semaglutide and tirzepatide labels, dosing errors and misleading marketing. In 2026, FDA also reminded compounders and telehealth companies that compounded drugs must meet legal conditions and that promotional claims cannot falsely imply safety, effectiveness or equivalence to approved products.
- Watch for vague phrases like research use or generic GLP-1.
- Be skeptical of ads promising equivalent results without an FDA-approved product.
- Check FDA updates because shortage and enforcement conditions can change.
The check we would not skip
Compounded drugs are not FDA-approved for safety, effectiveness or quality before marketing.
How to compare before checkout
A practical comparison should list brand name, active ingredient, dosage form, pharmacy, prescriber, lab policy, follow-up plan, refund terms and total monthly cost. A lower advertised price is not enough if the formulation, dose instructions or pharmacy source are unclear. For FDA-approved medications, compare the official label and manufacturer information; for compounded products, require a more detailed source and dosing explanation.
- Screenshot the final offer before entering payment details.
- Ask who manages side effects and dose changes.
- Compare FDA-approved coverage and cash-pay paths before choosing solely by price.
More questions and context
Common questions
Is compounded semaglutide a generic form of Wegovy or Ozempic?
No. FDA-approved generics undergo agency review and must meet approval requirements; compounded semaglutide is not FDA approved and is not an approved generic. FDA has warned telehealth companies not to market compounded products as generic or the same as approved drugs. FDA explains the distinction.
Can a pharmacy still compound semaglutide or tirzepatide after the shortages ended?
Potentially, but not simply because copies are cheaper or popular. The broad shortage-based transition periods have ended. A section 503A compounder may still fill an individual prescription when federal conditions are met, including a documented prescriber determination that a change produces a significant difference for that patient. FDA describes the current policy.
Does “made by an FDA-registered facility” mean the medication is FDA approved?
No. Registration as a section 503B outsourcing facility brings additional federal requirements, including current good manufacturing practices and FDA inspection, but it does not approve the facility’s compounded products. FDA explains what registration does and does not mean.
Do FDA adverse-event totals prove compounded GLP-1 products caused those events?
No. FDA says causation cannot always be determined. It also says reports are probably incomplete because traditional state-licensed pharmacies generally are not federally required to submit adverse-event reports. The totals are warning signals, not a direct comparison of event rates between compounded and approved products. FDA provides that context.
Is a prefilled compounded syringe automatically as straightforward as a brand pen?
No. A prefilled syringe may avoid drawing liquid from a multidose vial, but the compounded finished product still lacks FDA premarket review. Confirm its concentration, labeled amount, storage instructions, beyond-use date and who will answer administration questions. FDA reports that compounded products vary in packaging and concentration. See the FDA dosing-error alert.
Educational content only. Do not use this page as medical advice or as a substitute for a licensed clinician, pharmacist or insurer reviewing your situation.
Related checks
Sources and what to verify (6)
Sources
- FDA concerns with unapproved GLP-1 drugs
FDA safety context for unapproved GLP-1 products.
- FDA telehealth companies and compounded drugs
FDA marketing reminders for compounded-drug promotion.
- FDA: GLP-1 supply stabilization and compounding policy update
FDA update on semaglutide and tirzepatide shortage status and compounding enforcement timelines.
- FDA: warning letters for compounded GLP-1 marketing
FDA press announcement on warning letters to telehealth companies over compounded GLP-1 marketing claims.
- FDA label: Wegovy prescribing information
FDA-approved semaglutide weight-management label and safety information.
- FDA label: Zepbound prescribing information
FDA-approved tirzepatide weight-management label and safety information.